title: ARCTIC: assessment of haemodynamic response in patients with congestive heart failure to telmisartan: a multicentre dose-ranging study in Canada.
abstract: BACKGROUND
  The aim of this study was to examine the acute hemodynamic and neurohormonal effects of the angiotensin II antagonist telmisartan relative to placebo in patients with chronic symptomatic (New York Heart Association class II to III) congestive heart failure and to explore the dose-response relation for these effects.
  
  
  RESULTS
  After baseline hemodynamic and neurohormonal measurements made with the use of a pulmonary artery and radial arterial catheter, 82 patients were randomly assigned to placebo or 10, 20, 40, or 80 mg of telmisartan in a double-blind fashion. Hemodynamic and neurohormonal measurements were carried out over 24 hours. Telmisartan caused significant decreases in systemic arterial, pulmonary arterial, and pulmonary capillary wedge pressures with evidence of a dose-response relation for each of these parameters. The drug had no significant effects on heart rate, cardiac index, or systemic vascular resistance. Telmisartan did not have consistent effects on either plasma norepinephrine or plasma atrial natriuretic peptide levels, although it did cause significant increases in both plasma renin activity and angiotensin II levels at higher doses.
  
  
  CONCLUSIONS
  The acute administration of the angiotensin II antagonist telmisartan was associated with significant dose-dependent reductions in systemic arterial blood pressure and pulmonary pressures. Long-term follow-up studies are required to translate changes in hemodynamic parameters into a clinical benefit.
authors.affiliation: University of Ottawa Heart Institute, Ottawa, Canada.
authors.forename: A B
authors.initials: AB
authors.lastname: Parker
authors.forename: E R
authors.initials: ER
authors.lastname: Azevedo
authors.forename: M G
authors.initials: MG
authors.lastname: Baird
authors.forename: S J
authors.initials: SJ
authors.lastname: Smith
authors.forename: J M
authors.initials: JM
authors.lastname: Arnold
authors.forename: D P
authors.initials: DP
authors.lastname: Humen
authors.forename: G W
authors.initials: GW
authors.lastname: Moe
authors.forename: J O
authors.initials: JO
authors.lastname: Parker
authors.forename: R W
authors.initials: RW
authors.lastname: Butt
authors.forename: J D
authors.initials: JD
authors.lastname: Parker
mesh_terms: D000293:Adolescent; D000328:Adult; D000368:Aged; D000369:Aged, 80 and over; D000804:Angiotensin II / Q000097:blood; D000806:Angiotensin-Converting Enzyme Inhibitors / Q000008:administration & dosage*; D009320:Atrial Natriuretic Factor / Q000097:blood; D001562:Benzimidazoles / Q000008:administration & dosage*; D001565:Benzoates / Q000008:administration & dosage*; D002170:Canada; D002406:Catheterization, Peripheral; D003325:Coronary Care Units; D004305:Dose-Response Relationship, Drug; D004311:Double-Blind Method; D005260:Female; D006333:Heart Failure / Q000097:blood / Q000188:drug therapy* / Q000503:physiopathology; D006439:Hemodynamics / Q000187:drug effects*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009638:Norepinephrine / Q000097:blood; D012083:Renin / Q000097:blood; D012449:Safety; D000077333:Telmisartan; D016896:Treatment Outcome
chemical_list: D000806:Angiotensin-Converting Enzyme Inhibitors; D001562:Benzimidazoles; D001565:Benzoates; D000804:Angiotensin II; D009320:Atrial Natriuretic Factor; D012083:Renin; D000077333:Telmisartan; D009638:Norepinephrine